摘要
目的:分析替比夫治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法:考察53例替比夫定治疗HBeAg阳性慢性乙型病毒性肝炎患者的临床表现、生化学、病毒学和病毒基因耐药情况。结果:HBV DNA不可测率、ALT复常率、HBeAg消失率、HBeAg血清转换率和基因型耐药率分别为66.0%、83.7%、73.6%、13.2%和9.4%。结论:替比夫治疗HBeAg阳性慢性乙型肝炎具有良好的临床疗效。
Objective：To evaluate the clinical effect of telbivudine in patients with HBeAg-positive chronic hepatitis B（CHB）.Methods： The level of serum alanine aminotransferase（ALT）,HBV DNA,HBeAg loss,HBeAg seroconversion and genotype resistance of 53 patients with HBeAg-positive treated with telbivudine were compared.The average course of treatment was 22.2 months.Results：The rates of serum undetectable HBV DNA,normalization of ALT,HBeAg loss,HBeAg seroconversion and genotype resistance were 66.0%,83.7%,73.6%,13.2% and 9.4% respectively.Conclusion：Telbivudine was effective in patients with HBeAg-positive chronic hepatitis B.
出处
《西北国防医学杂志》
CAS
2011年第3期176-178,共3页
Medical Journal of National Defending Forces in Northwest China
关键词
慢性乙型肝炎
替比夫定
核苷类似物
Chronic hepatitis B
Telbivudine
Nucleoside/nucleotide analogue
